Orthopoxvirus Totally Explained

Everything about Orthopoxvirus totally explained

Orthopoxvirus is a genus of poxviruses that includes many species isolated from mammals, such as Buffalopox virus, Camelpox virus, Cowpox virus, Monkeypox virus, Rabbitpox virus, Sealpox virus, Volepox virus and Ectromelia virus, which causes mousepox. The most famous member of the genus is Variola virus, which causes smallpox. It was wiped out using another orthopoxvirus, the Vaccinia virus, as a vaccine.

Taxonomy

Members of the genus Orthopoxvirus are members of the family Poxviridae and the subfamily Chordopoxvirinae, members of which exclusively infect chordates.

Distribution

Some Orthopoxviruses have the ability to infect non-host species, such as monkeypox virus, which is capable of establishing infection in humans. Zoonoses of many of these mammalian isolates have been reported. Others are very specific for their hosts, for example myxoma virus, the cause of myxomatosis in rabbits, doesn't infect humans.

Human orthopoxvirus disease

Laboratory transmission

Aerosols of concentrated virus may result in Orthopox infection, especially in non-immunized individuals. Needle sticks, especially with concentrated virus, may result in severe local infection of the skin even in immunized individuals.

Signs and Symptoms

The initial symptoms include fever, malaise, head and body aches, and sometimes vomiting. Lesions that developed into crater-like ulcers surrounded by inflammatory tissue and eventually covered by thick black crusts are the characteristic indicators of Orthopox infection. Severe edema and erythema may affect large areas in cases of severe infection. Encephalitis (alteration of mental status and focal neurologic deficits), myelitis (upper- and lower-motor neuron dysfunction, sensory level and bowel and bladder dysfunction), or both may result from Orthopoxvirus infection. Rarely, Orthopoxviruses may be detected in cerebrospinal fluid. Some mammalian Orthopox infections are known to result in high instances of mortality.

Treatment

Vaccinia-specific immunoglobulins may be administered to infected individuals. The only product currently available for treatment of complications of Orthopox infection is Vaccinia Immunoglobulin (VIG), which is an isotonic sterile solution of the immunoglobulin fraction of plasma from persons vaccinated with vaccinia vaccine. It is effective for treatment of eczema vaccinatum and certain cases of progressive vaccinia. However, VIG is contraindicated for the treatment of vaccinial keratitis. VIG is recommended for severe generalized vaccinia if the patient is extremely ill or has a serious underlying disease. VIG provides no benefit in the treatment of postvaccinal encephalitis and has no role in the treatment of smallpox. Current supplies of VIG are limited, and its use should be reserved for treatment of vaccine complications with serious clinical manifestations. The recommended dosage of the currently available VIG for treatment of complications is 0.6 ml/kg of body weight. VIG must be administered intramuscularly and should be administered as early as possible after the onset of symptoms. Because therapeutic doses of VIG might be substantial (for example, 42 ml for a person weighing 70 kg), the product should be administered in divided doses over a 24- to 36-hour period. Doses can be repeated, usually at intervals of 2--3 days, until recovery begins (for example, no new lesions appear). Future reformulations of VIG might require intravenous administration, and health-care providers should refer to the manufacturer's package insert for correct dosages and route of administration. CDC is currently the only source of VIG for civilians (see Vaccinia Vaccine Availability for contact information). The Food and Drug Administration hasn't approved the use of any antiviral compound for the treatment of vaccinia virus infections or other Orthopoxvirus infections, including smallpox. Certain antiviral compounds (ST-246

) have been reported to be 100% active against vaccinia virus or other Orthopoxviruses in vitro and among test animals. ST-246 has been granted orphan drug status by the FDA and is currently under study to determine the safety and effectiveness in humans . Questions also remain regarding the effective dose and the timing and length of administration of these antiviral compounds. Insufficient information exists on which to base recommendations for any antiviral compound to treat post-vaccination complications or Orthopoxvirus infections, including smallpox. However, additional information could become available, and health-care providers should consult CDC to obtain up-dated information regarding treatment options for smallpox vaccination complications (see Consultation Regarding Complications of Vaccinia Vaccine).

Further Information

Get more info on 'Orthopoxvirus'.

External Link Exchanges

Do you know how hard it is to get a link from a large encyclopaedia? Well we're different and will prove it. To get a link from us just add the following HTML to your site on a relevant page:

<a href="http://orthopoxvirus.totallyexplained.com">Orthopoxvirus Totally Explained</a>

Then simply click through this link from your web page. Our crawlers will verify your link, extract the title of your web page and instantly add a link back to it. If you like you can remove the words Totally Explained and embed the link in article text.
As long as your link remains in place, we'll keep our link to you right here. Please play fair - our crawlers are watching. Your site must be closely related to this one's topic. Any kind of spamming, dubious practises or removing the link will result in your link from us being dropped and, potentially, your whole site being banned.